Zacks Investment Research on MSN

MRK gets positive CHMP opinion for expanded use of Winrevair in PAH

Merck MRK announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) has rendered ...
Nasdaq

Gilead, MRK Report Data From Investigational Combination Study for HIV

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational combination of islatravir and lenacapavir for the treatment of HIV. Data ...
Benzinga.com

Merck's Multi-Billion Cancer Drug Keytruda Aces Late-Stage Breast Cancer Study (UPDATED)

Keytruda demonstrated statistically significant and clinically meaningful improvement in OS compared to pre-operative chemotherapy. KEYNOTE 522 is the fourth study of a Keytruda-based regimen in an ...
Seeking Alpha

Merck Phase 3 study of Winrevair in PAH meets primary endpoint

Merck (NYSE:MRK) said a pivotal Phase 3 study for its drug Winrevair in the treatment of pulmonary arterial hypertension, or PAH, has met its primary endpoint. Topline results from the study, called ...
Seeking Alpha

Merck succeeds in late-stage study of PAH treatment

Merck (NYSE:MRK) said on Monday that its late-stage study, testing Winrevair (sotatercept) in adults with moderate to high risk pulmonary arterial hypertension, met the main goal. In the study, ...
Benzinga.com

After Failed Prostate Cancer Study Merck's Keytruda Combination Therapy Flunks In Late-Stage Lung Cancer Study

Thursday, Merck & Co Inc (NYSE:MRK) released topline data from the Phase 3 KEYLYNK-006 trial evaluating Keytruda (pembrolizumab) in combination with maintenance Lynparza (olaparib) for certain ...